SCHEMBL1820530

SCHEMBL1820530

O=C(O)c1cccc(Cl)c1C(=O)c1ccc(Cl)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.66
SRD5A2 P31213 2/20 0.55
TSHR P16473 3/20 0.53
ALDH1A1 P00352 5/20 0.52
FNTA P49354 2/20 0.50
FNTB P49356 2/20 0.50
ALOX15 P16050 1/20 0.50
PBRM1 Q86U86 1/20 0.49
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
GAA P10253 1/20 0.46
ALOX12 P18054 1/20 0.46
CYP2C19 P33261 1/20 0.46
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
AKR1C3 P42330 1/20 0.46
MAPK1 P28482 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CDC25B P30305 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5151524 0.89 ALDH1A1 (0.61) NR4A1SRD5A2TSHRALDH1A1ALOX15
SCHEMBL1819616 0.88 NR4A1 (0.69) NR4A1SRD5A2TSHRALDH1A1ALOX15
SCHEMBL21835148 0.86 ALDH1A1 (0.53) NR4A1SRD5A2TSHRALDH1A1ALOX15
SCHEMBL11850279 0.85 SRD5A2 (0.56) NR4A1SRD5A2TSHRALDH1A1ALOX15
SCHEMBL1821327 0.83 NR4A1 (0.62) NR4A1SRD5A2TSHRALDH1A1FNTA
SCHEMBL29583954 0.83 NR4A1 (0.62) NR4A1SRD5A2TSHRALDH1A1FNTA
SCHEMBL4801729 0.83 NR4A1 (0.62) NR4A1SRD5A2TSHRALDH1A1FNTA
SCHEMBL1246659 0.83 NR4A1 (0.62) NR4A1SRD5A2TSHRALDH1A1FNTA
SCHEMBL4551433 0.83 NR4A1 (0.62) NR4A1SRD5A2TSHRALDH1A1FNTA
SCHEMBL275485 0.81 TSHR (0.65) NR4A1TSHRALDH1A1ALOX15PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2960233-B1 NEW THERAPEUTIC AGENTS CANCER RESEARCH TECH LTD (GB) 2019-10-30 EP disclosed
US-10414726-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-09-17 US disclosed
US-10414726-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-09-17 US disclosed
US-20180118684-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-03 US disclosed
US-20180118684-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-03 US disclosed
US-20180118684-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-03 US disclosed
US-20160355478-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-12-08 US disclosed
US-20160355478-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-12-08 US disclosed
US-20160355478-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-12-08 US disclosed
US-9358222-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-07 US disclosed
US-20140194486-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-07-10 US disclosed
US-20140194486-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-07-10 US disclosed
US-20140194486-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-07-10 US disclosed
US-8618158-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-12-31 US disclosed
US-20110224274-A1 New Therapeutic Agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-09-15 US disclosed
US-20110224274-A1 New Therapeutic Agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-09-15 US disclosed
US-20110224274-A1 New Therapeutic Agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-09-15 US disclosed
EP-2315749-A2 NEW THERAPEUTIC AGENTS Cancer Research Technology Limited (GB) 2011-05-04 EP disclosed
WO-2009156735-A2 NEW THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-12-30 WO disclosed
US-4058529-A Polycyclic amino derivatives of pyrrolidone and piperidone CIBA-GEIGY CORPORATION (US) 1977-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194486-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 NR4A1 2664/4885SRD5A2 3092/4885TSHR 1949/4885
US-20110224274-A1 New Therapeutic Agents TP53, MDM2, TP53BP1 NR4A1 2295/4885SRD5A2 3329/4885TSHR 1980/4885
US-20180118684-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 NR4A1 2664/4885SRD5A2 3092/4885TSHR 1949/4885
US-10414726-B2 Therapeutic agents TP53, MDM2, TP53BP1 NR4A1 2664/4885SRD5A2 3092/4885TSHR 1949/4885
US-20160355478-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 NR4A1 2664/4885SRD5A2 3092/4885TSHR 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.